Related Experiment Video
Updated: May 4, 2026
PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
Published on: December 28, 2017
Assessment of early therapy response with 18F-FLT PET in glioblastoma multiforme
Matthew J Oborski1, Emre Demirci, Charles M Laymon
1From the Departments of *Radiology, and †Bioengineering, University of Pittsburgh, Pittsburgh, PA; ‡Department of Nuclear Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey; and §Division of Hematology/Oncology, Departments of Neurology and Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA.
Abstract:
Early therapy response assessment in glioblastoma multiforme remains a challenge. Evaluation by MRI relies on changes in tumor contrast enhancement or size, which are usually not visible at early therapy response assessment times. In addition, MRI may not be reliable for early therapy response assessment if only molecular changes have occurred. PET with F-FLT, a tracer associated with cellular proliferation, has been proposed as a potential method of early therapy response assessment and is an area of active research. We present a case where early response assessment with F-FLT PET was associated with a favorable 1-year follow-up outcome.
Insights
Early assessment of glioblastoma treatment response is difficult. Fluorine-18-fluorothymidine (F-FLT) Positron Emission Tomography (PET) shows promise for early detection of treatment efficacy, as seen in a case with favorable 1-year outcomes.
Area of Science:
- Neuro-oncology
- Medical imaging
- Radiochemistry
Background:
- Accurate early assessment of glioblastoma multiforme (GBM) treatment response is crucial but challenging with conventional MRI.
- MRI limitations include delayed detection of therapeutic effects, as changes in contrast enhancement or tumor size are often not apparent early in treatment.
- Molecular changes indicative of response may not be reliably detected by MRI.
Observation:
- F-18-fluorothymidine (F-FLT) Positron Emission Tomography (PET) is being investigated as a method for early therapy response assessment in GBM.
- F-FLT is a tracer that reflects cellular proliferation, offering a potential marker for treatment efficacy.
- This study presents a case demonstrating the utility of F-FLT PET for early response evaluation.
Findings:
- Early assessment using F-FLT PET in a glioblastoma patient indicated a positive response to therapy.
- The observed early response on F-FLT PET correlated with a favorable clinical outcome at 1-year follow-up.
- This suggests F-FLT PET may provide earlier and more reliable information than standard MRI.
Implications:
- F-FLT PET imaging may offer a valuable tool for optimizing early treatment strategies in glioblastoma.
- This approach could lead to timely treatment adjustments, potentially improving patient outcomes.
- Further research into F-FLT PET for glioblastoma response assessment is warranted.
![Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58641.jpg&w=3840&q=50)
